BRPI0912386A2 - composto, e, métodos para melhorar memória em um indivíduo e para tratar condições relacionadas a uma quinase - Google Patents

composto, e, métodos para melhorar memória em um indivíduo e para tratar condições relacionadas a uma quinase

Info

Publication number
BRPI0912386A2
BRPI0912386A2 BRPI0912386A BRPI0912386A BRPI0912386A2 BR PI0912386 A2 BRPI0912386 A2 BR PI0912386A2 BR PI0912386 A BRPI0912386 A BR PI0912386A BR PI0912386 A BRPI0912386 A BR PI0912386A BR PI0912386 A2 BRPI0912386 A2 BR PI0912386A2
Authority
BR
Brazil
Prior art keywords
individual
compound
methods
related conditions
improving memory
Prior art date
Application number
BRPI0912386A
Other languages
English (en)
Inventor
Karoly Nikolich
Laszlo Nadasdi
Original Assignee
Amnestix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amnestix Inc filed Critical Amnestix Inc
Publication of BRPI0912386A2 publication Critical patent/BRPI0912386A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0912386A 2008-05-12 2009-05-11 composto, e, métodos para melhorar memória em um indivíduo e para tratar condições relacionadas a uma quinase BRPI0912386A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5260008P 2008-05-12 2008-05-12
PCT/US2009/043467 WO2009140200A1 (en) 2008-05-12 2009-05-11 Compounds for improving learning and memory

Publications (1)

Publication Number Publication Date
BRPI0912386A2 true BRPI0912386A2 (pt) 2016-07-26

Family

ID=41319017

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0912337A BRPI0912337A2 (pt) 2008-05-12 2009-05-11 composto método para melhorar memória em paciente, e, método para tratar condições
BRPI0912386A BRPI0912386A2 (pt) 2008-05-12 2009-05-11 composto, e, métodos para melhorar memória em um indivíduo e para tratar condições relacionadas a uma quinase

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BRPI0912337A BRPI0912337A2 (pt) 2008-05-12 2009-05-11 composto método para melhorar memória em paciente, e, método para tratar condições

Country Status (10)

Country Link
US (3) US20110237600A1 (pt)
EP (2) EP2296472A4 (pt)
JP (2) JP2011519972A (pt)
KR (2) KR20110014183A (pt)
CN (2) CN102088853A (pt)
AU (2) AU2009246568A1 (pt)
BR (2) BRPI0912337A2 (pt)
CA (2) CA2723472A1 (pt)
MX (2) MX2010012104A (pt)
WO (2) WO2009140200A1 (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009140200A1 (en) * 2008-05-12 2009-11-19 Amnestix, Inc. Compounds for improving learning and memory
US8703736B2 (en) * 2011-04-04 2014-04-22 The Translational Genomics Research Institute Therapeutic target for pancreatic cancer cells
CN104582705A (zh) * 2012-01-10 2015-04-29 林伯士艾瑞斯公司 白介素-1受体相关激酶(irak)抑制剂和其用途
JP6437452B2 (ja) 2013-01-14 2018-12-12 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｐｉｍキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物
RS60244B1 (sr) 2013-01-15 2020-06-30 Incyte Holdings Corp Jedinjenja tiazolkarboksamida i piridinkarboksamida korisna kao inhibitori pim kinaze
CA2903082C (en) * 2013-03-04 2021-06-22 Advanced Medical Research Institute Of Canada Quinoline sulfonyl derivatives and uses thereof
CN105658653A (zh) 2013-08-23 2016-06-08 因赛特公司 可用作pim激酶抑制剂的呋喃并-和噻吩并-吡啶甲酰胺化合物
WO2015070170A1 (en) * 2013-11-08 2015-05-14 The Translational Genomics Research Institute Compounds for cognitive enhancement and methods of use thereof
CN105085478B (zh) * 2014-04-28 2019-04-12 南京明德新药研发股份有限公司 异喹啉磺胺衍生物及其药物组合物和制药用途
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Ｐｉｍ激酶抑制劑之鹽
US9920032B2 (en) 2015-10-02 2018-03-20 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
CA3005766A1 (en) 2015-12-17 2017-06-22 Merck Patent Gmbh Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders
JP7125385B2 (ja) * 2016-08-08 2022-08-24 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｔｌｒ７／８アンタゴニストおよびそれらの使用
JP6970295B2 (ja) * 2017-07-19 2021-11-24 チャイナ リソーシーズ ファーマシューティカル ホールディングス カンパニー リミテッド イソキノリニルスルホニル誘導体およびその使用
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
EP3843845B1 (en) 2018-08-29 2026-03-11 University Of Massachusetts Inhibition of protein kinases to treat friedreich ataxia
JP7377548B2 (ja) * 2018-10-15 2023-11-10 国立大学法人東海国立大学機構 抗精神病薬及びその用途
JP7766935B2 (ja) 2020-01-09 2025-11-11 ウールジー・ファーマシューティカルズ・インコーポレイテッド 皮質性認知症に関連する徘徊を治療する方法
EP4125910B1 (en) * 2020-03-25 2025-11-12 Woolsey Pharmaceuticals, Inc. Rho kinase inhibitors for treating frontotemporal dementia
CA3170073A1 (en) 2020-03-25 2021-09-30 Thomas Macallister Methods of treating proteinopathy- associated wandering
CA3175183A1 (en) 2020-04-23 2021-10-28 Thomas Macallister Methods of using rho kinase inhibitors to treat alzheimer's disease
MX2022015800A (es) * 2020-06-15 2023-01-24 Woolsey Pharmaceuticals Inc Metodos de uso de inhibidores de la quinasa rho para tratar demencia vascular.
EP4171564A4 (en) * 2020-06-25 2024-06-26 Woolsey Pharmaceuticals, Inc. METHODS FOR TREATING NEURODEVELOPMENTAL DISORDERS
EP4181925A4 (en) * 2020-07-14 2024-07-31 Woolsey Pharmaceuticals, Inc. METHODS OF TREATMENT OF PROTEINOPATHIES
WO2022046158A1 (en) * 2020-08-27 2022-03-03 Woolsey Pharmaceuticals, Inc Methods of treating age-related cognitive decline
US20230310447A1 (en) * 2020-08-28 2023-10-05 Woolsey Pharmaceuticals, Inc. Methods of treating age-related cognitive decline
MX2023004523A (es) * 2020-10-22 2023-05-08 Woolsey Pharmaceuticals Inc Metodos de tratamiento de tauopatias de 4 repeticiones.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4456757A (en) * 1981-03-20 1984-06-26 Asahi Kasei Kogyo Kabushiki Kaisha Isoquinolinesulfonyl derivatives and process for the preparation thereof
US4678783B1 (en) * 1983-11-04 1995-04-04 Asahi Chemical Ind Substituted isoquinolinesulfonyl compounds
NZ513800A (en) * 1996-08-12 2001-09-28 Welfide Corp Treatment of diseases using Rho kinase inhibitors
WO2000003746A2 (en) * 1998-07-14 2000-01-27 The Brigham And Women's Hospital, Inc. Upregulation of type iii endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
US7115607B2 (en) * 2001-07-25 2006-10-03 Amgen Inc. Substituted piperazinyl amides and methods of use
WO2003080649A2 (en) * 2002-03-20 2003-10-02 Regents Of The University Of Minnesota Induction of hepatocyte proliferation in vitro by inhibition of cell cycle inhibitors
ATE496893T1 (de) * 2002-12-20 2011-02-15 X Ceptor Therapeutics Inc Isochinolinonderivate und deren verwendung als medikamente
WO2004105757A2 (en) * 2003-05-29 2004-12-09 Schering Aktiengesellschaft Use of rho-kinase inhibitors in the treatment of aneurysm and cardiac hypertrophy
US20080096238A1 (en) * 2004-03-30 2008-04-24 Alcon, Inc. High throughput assay for human rho kinase activity with enhanced signal-to-noise ratio
WO2005117896A1 (de) * 2004-06-03 2005-12-15 Schering Aktiengesellschaft Formulierungen, die fasudil, eine matrix und einem mantel enthalten
KR101149954B1 (ko) * 2005-08-30 2012-06-01 아사히 가세이 파마 가부시키가이샤 술폰아미드 화합물
CN101321760A (zh) * 2005-10-06 2008-12-10 先灵公司 作为蛋白激酶抑制剂的吡唑并嘧啶
AU2007281701A1 (en) * 2006-08-10 2008-02-14 Translational Genomics Research Institute Compounds for improving learning and memory
WO2009140200A1 (en) * 2008-05-12 2009-11-19 Amnestix, Inc. Compounds for improving learning and memory

Also Published As

Publication number Publication date
EP2296472A1 (en) 2011-03-23
CA2723472A1 (en) 2009-12-17
WO2009151845A9 (en) 2010-01-28
WO2009151845A1 (en) 2009-12-17
AU2009257926A1 (en) 2009-12-17
AU2009246568A1 (en) 2009-11-19
CN102316737A (zh) 2012-01-11
MX2010012103A (es) 2011-04-04
CN102088853A (zh) 2011-06-08
US20110294789A1 (en) 2011-12-01
EP2296472A4 (en) 2011-06-08
JP2011519972A (ja) 2011-07-14
US20100160297A1 (en) 2010-06-24
KR20110011669A (ko) 2011-02-08
CA2725416A1 (en) 2009-11-19
WO2009140200A1 (en) 2009-11-19
MX2010012104A (es) 2011-04-05
US20110237600A1 (en) 2011-09-29
KR20110014183A (ko) 2011-02-10
EP2285217A1 (en) 2011-02-23
BRPI0912337A2 (pt) 2019-09-24
JP2011519973A (ja) 2011-07-14
EP2285217A4 (en) 2011-06-08

Similar Documents

Publication Publication Date Title
BRPI0912386A2 (pt) composto, e, métodos para melhorar memória em um indivíduo e para tratar condições relacionadas a uma quinase
BRPI0918170A2 (pt) método, e, composição endurecível
BRPI0919575A2 (pt) método, e, composição
BRPI0913227A2 (pt) método, e objeto
BRPI1013878A2 (pt) método para tratar distúrbios metabólicos, e, composto
BRPI0909627A2 (pt) métodos, composições e kits para tratar dores e pruridos
BRPI0916787A2 (pt) artigo, e, método para fabricar um artigo
BRPI0809655A2 (pt) Método para tratar uma condição em um mamífero, composição farmacêutica, e, kit
BRPI0918642A2 (pt) coque e método para fabricação do mesmo.
BRPI0912384A2 (pt) composição, e, método para preparar uma composição
BRPI0814467A2 (pt) Método, e, biocombustível
BRPI0913752A2 (pt) método, dispositivo, e, estrutura
BRPI0809573A2 (pt) composição, e, método
BRPI0908092A2 (pt) Edulcorante, método para preparar uma composição edulcorante, e, composição edulcorante
BRPI0921579A2 (pt) método para ligar dinamicamente programa em plataforma embutida e plataforma embutida
BRPI0814299A2 (pt) Preparação sólida, e, métodos para estabilizar um composto em uma preparação sólida, e para produzir uma preparação sólida
BRPI0920284A2 (pt) composição e método
EP2311039A4 (en) MULTIMODAL MEMORY DEVICE AND METHOD
BRPI0921317A2 (pt) composto, composição farmacêutica, e, método para tratar ou prevenir uma patologia relacionada com abeta em um mamífero
BRPI0914789A2 (pt) efeitos sinérgicos
BRPI0817751A2 (pt) método para suprimir a proliferação de células de tumor, e, composição
DK2238213T3 (da) Trans-chlor-3,3,3-trifluorpropen til anvendelse i køleindretninger
BRPI0917637A2 (pt) método, e, dispositivo de armazenamento de hardware
BRPI0822365A2 (pt) Conjunto de ferramenta de fundo de furo, e, método para perfilar
EP2383750A4 (en) MEMORY CONTROLLER AND MEMORY MANAGEMENT PROCESS

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A, 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]